Arsenal Biosciences
South San Francisco, CA · Founded 2018 · CIK 0001945638 · Biotech · Private
Programmable cell therapies for solid tumors
arsenalbio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $579M
- 3 Form D · Sep 2024
- 25 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 5 granted · 35 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $220,806,682 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $32,999,954 | |
| Private capital raised | Form D · SEC | $325,352,578 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2771 | Niche Biopharmaceuticals LLC | — | $525K |
| 2772 | LACERTA THERAPEUTICS, INC. | — | $500K |
| 2773 | StaphOff Biotech, Inc. | — | $25K |
| 2774 | Arsenal Biosciences | — | $579M |
| 2775 | Invivyd, Inc. | — | $489M |
| 2776 | Recursion Pharmaceuticals, LLC | — | $466M |
| 2777 | CARTESIAN THERAPEUTICS INC | — | $446M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- James AhlersExecutive Officer
- Valentin BarsanDirector
- Brook ByersDirector
- Kenneth DrazanDirector · Executive Officer
- Matthew FustDirector
- Margaret NibbiExecutive Officer
- Sean ParkerDirector
- Irene PleasureExecutive Officer
- Beth SeidenbergDirector
Patents
- Synthetic Pathway Activatorsapplication
- Synthetic Pathway Activatorsgranted
- Novel Receptors For Transcription Regulationapplication
- Synthetic Pathway Activatorsapplication
- Immune Cells Having Co-expressed Shrnas And Logic Gate Systemsapplication
- Immune Cells With Combination Gene Perturbationsapplication
- Immune Cells Having Co-expressed Tgfbr Shrnasapplication
- Systems Targeting Psma And CA9granted
- Systems Of Engineered Receptors Targeting Psma And CA9application
- Cells Comprising A Suppressor Of Gene Expression And/or A Syntheticpathway Activator And/or An Inducible Payloadapplication
- Immune Cells Having Co-expressed Shrnas And Logic Gate Systemsapplication
- Non-viral Homology Mediated End Joiningapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.